Seeking Alpha

Celgene's (CELG -0.2%) Apremilast treatment for psoriatic arthritis was effective in a Phase III...

Celgene's (CELG -0.2%) Apremilast treatment for psoriatic arthritis was effective in a Phase III trial and had no major safety problems. The study is the first of three trials of the drug, and Celgene expects to file for FDA approval in H1 next year. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|